Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Short term Debt (2016 - 2022)

IGC Pharma has reported Short term Debt over the past 9 years, most recently at $3000.0 for Q2 2022.

  • Quarterly Short term Debt changed 0.0% to $3000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Jun 2022, changed 0.0% year-over-year, with the annual reading at $3000.0 for FY2022, 99.01% down from the prior year.
  • Short term Debt was $3000.0 for Q2 2022 at IGC Pharma, roughly flat from $3000.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $304000.0 in Q1 2021 and troughed at $3000.0 in Q2 2021.
  • The 4-year median for Short term Debt is $50000.0 (2019), against an average of $78230.8.
  • Year-over-year, Short term Debt surged 508.0% in 2021 and then tumbled 99.01% in 2022.
  • A 4-year view of Short term Debt shows it stood at $50000.0 in 2019, then surged by 404.0% to $252000.0 in 2020, then crashed by 98.81% to $3000.0 in 2021, then changed by 0.0% to $3000.0 in 2022.
  • Per Business Quant, the three most recent readings for IGC's Short term Debt are $3000.0 (Q2 2022), $3000.0 (Q1 2022), and $3000.0 (Q4 2021).